Stockscreener 앱 받기
123.16
1.59%
1.79
전일 마감가:
$121.37
열려 있는:
$121.55
하루 거래량:
7.82M
Relative Volume:
0.76
시가총액:
$N/A
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+7.69%
1개월 성능:
+13.76%
6개월 성능:
+56.00%
1년 성능:
+24.73%
1일 변동 폭
$120.95
$123.47
1주일 범위
$113.57
$123.47
52주 변동 폭
$66.66
$123.47
State Street Spdr S P Biotech Etf Stock (XBI) Company Profile
XBI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XBI
State Street Spdr S P Biotech Etf
|
123.25 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
334.95 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
680.64 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
683.69 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
258.08 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
614.52 | 124.43B | 0 | 0 | 0 | 0.00 |
State Street Spdr S P Biotech Etf 주식(XBI)의 최신 뉴스
Apple, Taiwan Semiconductor Manufacturing And More On CNBC's 'Final Trades' - Benzinga
Best-Performing ETFs of Last Week: Healthcare Rules - sharewise.com
Why biotech and drug stocks are on the mend even though the rest of the market is hurting - MSN
ETFs Investing in Janux Therapeutics, Inc. Stocks - TradingView
3 Biotech Stocks Wall Street Analysts Predict Will More Than Double - Markets Financial Content
S&P 500: Health Care Stocks Come Alive — Nudging Tech Aside For Now - Investor's Business Daily
Biotech ETF (XBI) Hits New 52-Week High - MSN
Biotech Stock Gets Booted in Latest Fund Update - The Motley Fool
Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now? - sharewise.com
(11/19/25) PFE: The Winner in the Metsera Bidding War - moneyshow.com
Why biotech and drug stocks are rallying even though the rest of the market is hurting - MarketWatch
M&A Injects Life Into Biotech Trade - TheStreet Pro
XBI: Biotech Funding Condition Recovery Could Be Overdue (NYSEARCA:XBI) - Seeking Alpha
XBI: An Equal Weight ETF On Biotech That Amplifies Its Speculative Component - Seeking Alpha
Breakthrough bets on life sciences rebound with $430m fundraise - Private Equity Real Estate | PERE
This Biotech Stock Soared 100%. Merck Is Buying It. - Barron's
META_TITLE_SECTORS - Yahoo Finance
Two Biotech Stocks to Watch as Sector Bounces Back - TheStreet Pro
Should You Invest in the State Street SPDR S&P Semiconductor ETF (XSD)? - Yahoo Finance
Should You Invest in the State Street SPDR S&P Oil & Gas Exploration & Production ETF (XOP)? - Nasdaq
Is State Street SPDR S&P Retail ETF (XRT) a Strong ETF Right Now? - sharewise.com
Is State Street SPDR S&P Bank ETF (KBE) a Strong ETF Right Now? - Yahoo Finance
Should You Invest in the State Street SPDR S&P Retail ETF (XRT)? - Nasdaq
Is the Drought in Life-Sciences IPOs Over? Two Startups Will Test Demand - The Wall Street Journal
Experiments, Mergers, and Interest Rate Cuts: The Biotechnology Sector Ushers in a New Cycle - NAI500
SPDR S&P Biotech ETF declares quarterly distribution of $0.0267 - MSN
SPDR S&P Biotech ETF Options Spot-On: On November 3rd, 78,510 Contracts Were Traded, With 811.5K Open Interest - 富途牛牛
SPDR S&P Biotech ETF (XBI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Biotech ETFs Come Alive As Illumina Soars 23% — Is The Genomics Winter Finally Over? - Benzinga
Biopharmaceutical stocks performed strongly against the market trend, bolstered by industry mergers and acquisitions as well as favorable policy developments. - 富途牛牛
It's a high-risk trade, but this biotech down 80% this year could be a buy - CNBC
Top 6 ETFs To Watch As Wall Street's Strongest Six Months Begin - Benzinga
Biotech ETFs Hovering Around a 52-Week: Here's Why - TradingView
Why Is Intellia Therapeutics Stock Sinking Monday?Intellia Therapeutics (NASDAQ:NTLA) - Benzinga
StockWatch: Top 3 Biotech ETFs Finally Bounce Back with the Market - Genetic Engineering and Biotechnology News
Have Biotech Stocks Returned To Health After Years Of Sickness? - Investor's Business Daily
Analyst Says He’s Buying This Biotech ETF, Predicts ‘Multi-Year’ Breakout - Insider Monkey
Guarantor: JPMorgan Chase & Co. - StreetInsider
Biotech Is Finally Rallying. Why Mizuho’s Jared Holz Is Optimistic This Time. - Barron's
XBI, CRSP, INSM, IONS: Large Inflows Detected at ETF - Nasdaq
The Technical Signals Behind (XBI) That Institutions Follow - news.stocktradersdaily.com
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures - Benzinga
(XBI) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
(XBI) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Discipline and Rules-Based Execution in XBI Response - news.stocktradersdaily.com
XPH: Small-Cap Pharma Turns Higher, At Long Last (NYSEARCA:XPH) - Seeking Alpha
Precision Trading with Spdr Biotech Etf (XBI) Risk Zones - news.stocktradersdaily.com
String of acquisitions fuels biotech optimism - Sherwood News
Should You Invest in the SPDR S&P Biotech ETF (XBI)? - Yahoo Finance
Truist Financial Corp Sells 5,213 Shares of SPDR S&P Biotech ETF $XBI - Defense World
Vontobel Holding Ltd. Sells 7,846 Shares of SPDR S&P Biotech ETF $XBI - Defense World
State Street Spdr S P Biotech Etf (XBI) 재무 분석
State Street Spdr S P Biotech Etf (XBI)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.86%
자본화:
|
볼륨(24시간):